Prevalence and Risk Factors of Hepatic Fibrosis in Patients with Nonalcoholic Fatty Liver (NAFLD) Samutsakhon Hospital: A Pilot Study
Keywords:
nonalcoholic fatty liver disease (NAFLD), fibrosisAbstract
Objective: The aim was to study the prevalence of hepatic fibrosis and the level of fat accumulation, as well as to find risk factors for fat accumulation and fibrosis in patients with nonalcoholic fatty liver in Samutsakhon Hospital.
Methods: This is a pilot study. The data were collected from the recording form of patients with fatty liver who came to be examined with a FIbroScan machine at the Liver Disease Clinic in Samutsakhon Hospital on 27 June 2024. The data were analyzed using mean, median, mode, range, odds ratio, 95% CI, and p-value.
Result: The patients with fatty liver had an average age of 51.3 ± 11.7 years; the majority were female, 48 patients (61.5%). The average BMI was 28.8 ± 5.3 with the body mass index more than 30 in 32 patients (41%). Fifteen patients (19.2%) has history of smoking. Most had a waist circumference of more than 90 centimeters, 50 patients (64.1%); and a waist-to-height ratio of more than or equal to 0.5, 69 patients (88.5%). The most common comorbidities found were hyperlipidemia in 33 patients (42.3%); followed by hypertension, 27 patients (34.6%); and diabetes, 18 patients (23.1%).
When examining patients with fatty liver using a FibroScan machine, 41 cases (52.6%) were S0, 10 cases were S1 (12.8%), 5 cases were S2 (6.4%), 22 cases were S3 (28.2%), and 61 cases (78.2%) were F0–F1, 6 cases were F1–F2 (7.7%), 3 cases were F2–F3 (3.8%), and 8 cases were F3–F4 (10.3%).
Conclusions: Fatty liver disease were found to have fat accumulation in liver of 47.8% and 21.8 percent of patients with fatty liver disease had liver fibrosis of F1–F4. Moreover; waist circumference of more than 80 and 90 centimeters had a significant risk of fat accumulation at liver in patients with fatty liver disease (p-value < .01), waist circumference >90 centimeters or S3 fat accumulation had a significant risk of liver fibrosis of F2–F4 levels (p-value < .05), and those who smoked had a significant risk of liver fibrosis of F2–F4 levels (p-value < .01).
References
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84. doi: 10.1002/hep.28431
Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: are we there yet? Metabolism 2016;65(8):1087–95. doi: 10.1016/j.metabol.2016.01.013
Rinella ME, Sanyal AJ. Management of nafld: a stage-based approach. Nat Rev Gastroenterol Hepatol 2016;13(4):196–205. doi: 10.1038/ nrgastro. 2016.3
Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatology 2023;8(1):20–30. doi: 10.1016/S2468-1253(22)00317-X
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388–402. doi: 10.1016/j.jhep.2015.11.004
Buday B, Pach PF, Literati-Nagy B, et al. Sex influenced association of directly measured insulin sensitivity and serum transaminase levels: Why alanine aminotransferase only predicts cardiovascular risk in men? Cardiovasc Diabetol 2015;14:55. doi: 10.1186/s12933-015-0222-3.
Boonchai P, Kositamongkol C, Jitrukthai S, et al. Clinical differences and non-alcoholic fatty liver disease-related factors of lean and non-lean patients with metabolic syndrome. J Clin Med 2022;11(9):2445. doi: 10.3390/jcm11092445.
Summart U, Thinkhamrop B, Chamadol N, et al. Gender differences in the prevalence of nonalcoholic fatty liver disease in the Northeast of Thailand: a population-based cross-sectional study. F1000Res 2017;6:1630. doi: 10.12688/f1000research.12417.2
Phisalprapa P, Prasitwarachot R, Kositamongkol C, et al. Economic burden of non-alcoholic steatohepatitis with signifcant fibrosis in Thailand. BMC Gastroenterol 2021;21:135. doi: 10.1186/s12876-021-01720-w
Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51(2):454–62. doi: 10.1002/hep.23312
Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2019;17(1):156–63. doi: 10.1016%2Fj.cgh.2018.04.043.
Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017;66(5):1022–30. doi: 10.1016/j.jhep.2016.12.022.
Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156(6):1717–30. doi: 10.1053/j.gastro.2019.01.042
Boursier J, Zarski J-P, de Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013;57(3):1182–91.
doi: 10.1002/hep.25993.
Jinjuvadia R, Antaki F, Lohia P, et al. The association between nonalcoholic fatty liver disease and metabolic abnormalities in The United States Population. J Clin Gastroenterol 2017;51(2):160–6. doi: 10.1097/MCG.0000000000000666
Goyal A, Arora H, Arora S. Prevalence of fatty liver in metabolic syndrome. J Family Med Prim Care 2020;9(7):3246–50. doi: 10.4103/jfmpc.jfmpc_1108_19
Shaikh MA, Bhanuprakash P. Study of non-alcoholic fatty liver disease in metabolic syndrome. Int J Adv Med 2018;5(6):1465–69. doi: 10.18203/2349-3933.ijam20184758
Ramirez-Mejia MM, Mendez-Sanchez N. What is in a name: from NAFLD to MAFLD and MASLD – Unraveling the complexities and implications. Current Hepatology reports 2023;22(4):221–7. doi: 10.1007/s11901-023-00620-9
Shon H, Lei S, Yiwei H, et al. From NAFLD to MASLD: when metabolic comorbidity matters. Ann Hepatol 2024;29(2):101281. doi: 10.1016/j.aohep.2023.101281
Rui S, Zhao L, Yingzhi Z, et al. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United states adults. Liver Int 2024;44(4):1051–60. doi: 10.1111/liv.15856.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ลิขสิทธิ์บทความเป็นของผู้เขียนบทความ แต่หากผลงานของท่านได้รับการพิจารณาตีพิมพ์ลงวารสารแพทย์เขต 4-5 จะคงไว้ซึ่งสิทธิ์ในการตีพิมพ์ครั้งแรกด้วยเหตุที่บทความจะปรากฎในวารสารที่เข้าถึงได้ จึงอนุญาตให้นำบทความในวารสารไปใช้ประโยชน์ได้ในเชิงวิชาการโดยจำเป็นต้องมีการอ้างอิงถึงชื่อวารสารอย่างถูกต้อง แต่ไม่อนุญาตให้นำไปใช้ในเชิงพาณิชย์
